Survival of untreated advanced colorectal cancer patients

Stathopoulos,G. P.

doi:10.3892/ol.2011.310

Survival of untreated advanced colorectal cancer patients

Authors:
- G. P. Stathopoulos
View Affiliations

Affiliations: First Oncology Clinic, Errikos Dunant Hospital, Athens, Greece
Published online on: May 13, 2011 https://doi.org/10.3892/ol.2011.310
Pages: 731-733

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Colorectal cancer has specific biological characteristics that distinguish it from other malignancies. One such characteristic is its slow growth in patients in advanced stages. For the past 15 years, no effective systemic treatment has been available in clinical practice. The present study involved a retrospective evaluation of patients with advanced colorectal cancer in order to assess the median and overall survival of patients. Concurrently, the study aimed to describe the biological characteristics of this slow-growing disease and the quality of life of the patients. The key characteristic of this patient group was the lack of any systemic treatment. The study included 40 patients (25 male and 15 female, median age 67 years) who were evaluated between 1993 and 1996. Only supportive treatment was provided. One patient underwent 2 cycles of chemotherapy. Liver surgery was unsuccessfully performed on 3 patients. Two patients underwent radiofrequency once and 2 had intra-arterial treatment, also once. The results showed the median survival of patients to be 24 months (range 16-42). One-year survival was found to be 65% while the 2-year survival was found to be 25%. A satisfactory quality of life was also observed. In conclusion, colorectal cancer is a slow-going malignancy, as indicated by the long-term survival of patients and the biological characteristics of the tumor.

View Figures

View References

1	Gastrointestinal Tumor Study Group. Adjuvant therapy for colon cancer: results of a prospectively randomized trial. N Engl J Med. 310:737–740. 1984. View Article : Google Scholar : PubMed/NCBI
2	Mulcahy HE, Toner M, Patchett SE, et al: Identifying stage B colorectal cancer patients at high risk of tumor recurrence and death. Dis Colon Rectum. 40:326–336. 1997. View Article : Google Scholar : PubMed/NCBI
3	Moertel CG: Chemotherapy of gastrointestinal cancer. Recent Advances in Cancer Treatment. Tajnon HJ and Staquet MJ: New York: Raven Press; pp. 311–323. 1997
4	Wolmark N, Rockette H, Fisher B, et al: The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project. Protocol C-03. J Clin Oncol. 11:1879–87. 1993.
5	Francini GP and Lorenzini L: Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. Gastroenterology. 106:899–906. 1994.PubMed/NCBI
6	De Gramont A, Vignoud J, Tournigand C, et al: Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer. 33:214–219. 1997.
7	Rougier P, Van Cutsem E, Bajetta E, et al: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet. 352:1407–1412. 1998. View Article : Google Scholar
8	Sargent DJ, Niedzwiecki D, O’ Conell MJ, et al: Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med. 345:144–145. 2001. View Article : Google Scholar : PubMed/NCBI
9	De Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 18:2938–2947. 2000.
10	Scheithauer W, Kornek GV, Raderer M, et al: Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer. J Clin Oncol. 17:902–906. 1999.
11	Rothenberg ML: Efficiacy of oxaliplatin in the treatment of colorectal cancer. Oncology. 14:9–14. 2000.PubMed/NCBI
12	Souglakos J, Mavroudis D, Kakolyris S, et al: Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial. J Clin Oncol. 20:2651–2657. 2002. View Article : Google Scholar
13	Scheithauer W, Kornek GV, Raderer M, et al: Randomized multicenter Phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 21:1307–1312. 2003. View Article : Google Scholar : PubMed/NCBI
14	Goldberg RM, Sargent DJ, Morton RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 22:23–30. 2004. View Article : Google Scholar
15	Stathopoulos GP, Rigatos SK, Stathopoulos JG, Xynotroulas JP and Dimou E: Efficacy and tolerability of oxaliplatin plus irinotecan 5-fluorouracil and leucovorin regimen in advanced stage colorectal cancer patients pretreated with irinotecan, 5-fluorouracil and leucovorin. AJ Clin Oncol. 28:565–569. 2005. View Article : Google Scholar : PubMed/NCBI
16	Stathopoulos GP, Rigatos SK, Malamos N, et al: Long term survival of patients with advanced colorectal cancer may not be due to the response to chemotherapy. Oncology Rep. 12:1295–1300. 2004.PubMed/NCBI
17	Therasse P, Arbuck SG, Eisenhower E, et al: New guidelines to evaluate the response to tumor in solid tumors. JNCI. 92:205–216. 2000. View Article : Google Scholar : PubMed/NCBI
18	Cunningham D, Pyrhonen S, James RD, et al: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet. 31(353): 1275–1276. 1999.PubMed/NCBI